The initial results of MRI-TRUS fusion prostate biopsy in high volume tertiary center

1. Culp MB, Soerjomataram I, Efstathiou JA, Bray F and Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol 2020; 77: 38–52. doi: 10.1016/j.eururo.2019.08.005 CulpMB SoerjomataramI EfstathiouJA BrayF JemalA Recent global patterns in prostate cancer incidence and mortality rates Eur Urol 2020 77 38 52 10.1016/j.eururo.2019.08.005 Open DOISearch in Google Scholar

2. Zadnik V, Gašljević G, Hočevar M, Jarm K, Pompe-Kirn V, Strojan P, et al. Cancer in Slovenia 2019. [Internet]. Oncology Institute Ljubljana. Cancer Epidemiology and Registry. Cancer Registry of the Republic of Slovenia; 2022. p. 1–65. [cited 2024 May 27]. Available at: https://www.onko-i.si/rrs ZadnikV GašljevićG HočevarM JarmK Pompe-KirnV StrojanP Cancer in Slovenia 2019 [Internet]. Oncology Institute Ljubljana. Cancer Epidemiology and Registry. Cancer Registry of the Republic of Slovenia 2022 1 65 [cited 2024 May 27]. Available at: https://www.onko-i.si/rrs Search in Google Scholar

3. Cornford P, Tilki D, van den Bergh RCN, Briers E, Eberli D, De Meerleer M, et al. Prostate cancer. EAU guidelines 2024. [Internet]. European Association of Urology; 2024. [cited 2024 May 27]. Available at: https://uroweb.org/guidelines/prostate-cancer CornfordP TilkiD van den BerghRCN BriersE EberliD De MeerleerM Prostate cancer EAU guidelines 2024 [Internet]. European Association of Urology 2024 [cited 2024 May 27]. Available at: https://uroweb.org/guidelines/prostate-cancer Search in Google Scholar

4. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS and Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909–16. doi: 10.1056/NEJM198710083171501 StameyTA YangN HayAR McNealJE FreihaFS RedwineE Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate N Engl J Med 1987 317 909 16 10.1056/NEJM198710083171501 Open DOISearch in Google Scholar

5. Sokoll LJ, Chan DW, Mikolajczyk SD, Rittenhouse HG, Evans CL, Linton HJ, et al. Proenzyme psa for the early detection of prostate cancer in the 2.5–4.0 ng/ml total psa range: preliminary analysis. Urology 2003; 61: 274–6. doi: 10.1016/s0090-4295(02)02398-1 SokollLJ ChanDW MikolajczykSD RittenhouseHG EvansCL LintonHJ Proenzyme psa for the early detection of prostate cancer in the 2.5–4.0 ng/ml total psa range: preliminary analysis Urology 2003 61 274 6 10.1016/s0090-4295(02)02398-1 Open DOISearch in Google Scholar

6. Hedelin H, Johansson N and Stroberg P. Relationship between benign prostatic hyperplasia and lower urinary tract symptoms and correlation between prostate volume and serum prostate-specific antigen in clinical routine. Scand J Urol Nephrol 2005; 39: 154–9. doi: 10.1080/00365590510007685 HedelinH JohanssonN StrobergP Relationship between benign prostatic hyperplasia and lower urinary tract symptoms and correlation between prostate volume and serum prostate-specific antigen in clinical routine Scand J Urol Nephrol 2005 39 154 9 10.1080/00365590510007685 Open DOISearch in Google Scholar

7. Chambo RC, Tsuji FH, de Oliveira Lima F, Yamamoto HA and de Jesus CM. What is the ideal core number for ultrasound-guided prostate biopsy? Korean J Urol 2014; 55: 725–31. doi: 10.4111/kju.2014.55.11.725 ChamboRC TsujiFH de Oliveira LimaF YamamotoHA de JesusCM What is the ideal core number for ultrasound-guided prostate biopsy? Korean J Urol 2014 55 725 31 10.4111/kju.2014.55.11.725 Open DOISearch in Google Scholar

8. Walz J, Graefen M, Chun FK, Erbersdobler A, Haese A, Steuber T, et al. High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. Eur Urol 2006; 50: 498–505. doi: 10.1016/j.eururo.2006.03.026 WalzJ GraefenM ChunFK ErbersdoblerA HaeseA SteuberT High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series Eur Urol 2006 50 498 505 10.1016/j.eururo.2006.03.026 Open DOISearch in Google Scholar

9. Bell KJ, Del Mar C, Wright G, Dickinson J and Glasziou P. Prevalence of incidental prostate cancer: a systematic review of autopsy studies. Int J Cancer 2015; 137: 1749–57. doi: 10.1002/ijc.29538 BellKJ Del MarC WrightG DickinsonJ GlasziouP Prevalence of incidental prostate cancer: a systematic review of autopsy studies Int J Cancer 2015 137 1749 57 10.1002/ijc.29538 Open DOISearch in Google Scholar

10. Jansen FH, van Schaik RH, Kurstjens J, Horninger W, Klocker H, Bektic J, et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010; 57: 921–7. doi: 10.1016/j.eururo.2010.02.003 JansenFH van SchaikRH KurstjensJ HorningerW KlockerH BekticJ Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection Eur Urol 2010 57 921 7 10.1016/j.eururo.2010.02.003 Open DOISearch in Google Scholar

11. Loeb S and Catalona WJ. The Prostate Health Index: a new test for the detection of prostate cancer. Ther Adv Urol 2014; 6: 74–7. doi: 10.1177/1756287213513488 LoebS CatalonaWJ The Prostate Health Index: a new test for the detection of prostate cancer Ther Adv Urol 2014 6 74 7 10.1177/1756287213513488 Open DOISearch in Google Scholar

12. Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008; 179: 1587–92. doi: 10.1016/j.juro.2007.11.038 DerasIL AubinSM BlaseA DayJR KooS PartinAW PCA3: a molecular urine assay for predicting prostate biopsy outcome J Urol 2008 179 1587 92 10.1016/j.juro.2007.11.038 Open DOISearch in Google Scholar

13. Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, Jannink SA, et al. Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score. Eur Urol 2016; 70: 740–8. doi: 10.1016/j.eururo.2016.04.012 Van NesteL HendriksRJ DijkstraS TrooskensG CornelEB JanninkSA Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score Eur Urol 2016 70 740 8 10.1016/j.eururo.2016.04.012 Open DOISearch in Google Scholar

14. Futterer JJ. Multiparametric MRI in the detection of clinically significant prostate cancer. Korean J Radiol 2017; 18: 597–606. doi: 10.3348/kjr.2017.18.4.597 FuttererJJ Multiparametric MRI in the detection of clinically significant prostate cancer Korean J Radiol 2017 18 597 606 10.3348/kjr.2017.18.4.597 Open DOISearch in Google Scholar

15. Drost FH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev 2019; 4: CD012663. doi: 10.1002/14651858.CD012663.pub2 DrostFH OssesDF NieboerD SteyerbergEW BangmaCH RoobolMJ Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer Cochrane Database Syst Rev 2019 4 CD012663 10.1002/14651858.CD012663.pub2 Open DOISearch in Google Scholar

16. Bratan F, Niaf E, Melodelima C, Chesnais AL, Souchon R, Mege-Lechevallier F, et al. Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study. Eur Radiol 2013; 23: 2019–29. doi: 10.1007/s00330-013-2795-0 BratanF NiafE MelodelimaC ChesnaisAL SouchonR Mege-LechevallierF Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study Eur Radiol 2013 23 2019 29 10.1007/s00330-013-2795-0 Open DOISearch in Google Scholar

17. Futterer JJ, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A, et al. Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur Urol 2015; 68: 1045–53. doi: 10.1016/j.eururo.2015.01.013 FuttererJJ BrigantiA De VisschereP EmbertonM GiannariniG KirkhamA Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature Eur Urol 2015 68 1045 53 10.1016/j.eururo.2015.01.013 Open DOISearch in Google Scholar

18. Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol 2016; 69: 16–40. doi: 10.1016/j.eururo.2015.08.052 WeinrebJC BarentszJO ChoykePL CornudF HaiderMA MacuraKJ PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2 Eur Urol 2016 69 16 40 10.1016/j.eururo.2015.08.052 Open DOISearch in Google Scholar

19. Xu G, Li JH, Xiang LH, Yang B, Chen YC, Sun YK, et al. Transrectal ultrasound examination of prostate cancer guided by fusion imaging of multiparametric MRI and TRUS: avoiding unnecessary mpMRI-guided targeted biopsy. Asian J Androl 2023; 25: 410–5. doi: 10.4103/aja202276 XuG LiJH XiangLH YangB ChenYC SunYK Transrectal ultrasound examination of prostate cancer guided by fusion imaging of multiparametric MRI and TRUS: avoiding unnecessary mpMRI-guided targeted biopsy Asian J Androl 2023 25 410 5 10.4103/aja202276 Open DOISearch in Google Scholar

20. Littrup PJ and Bailey SE. Prostate cancer: the role of transrectal ultrasound and its impact on cancer detection and management. Radiol Clin North Am 2000; 38: 87–113. doi: 10.1016/s0033-8389(05)70151-2 LittrupPJ BaileySE Prostate cancer: the role of transrectal ultrasound and its impact on cancer detection and management Radiol Clin North Am 2000 38 87 113 10.1016/s0033-8389(05)70151-2 Open DOISearch in Google Scholar

21. Wegelin O, Exterkate L, van der Leest M, Kummer JA, Vreuls W, de Bruin PC, et al. The FUTURE Trial: a multicenter randomised controlled trial on target biopsy techniques based on magnetic resonance imaging in the diagnosis of prostate cancer in patients with prior negative biopsies. Eur Urol 2019; 75: 582–90. doi: 10.1016/j.eururo.2018.11.040 WegelinO ExterkateL van der LeestM KummerJA VreulsW de BruinPC The FUTURE Trial: a multicenter randomised controlled trial on target biopsy techniques based on magnetic resonance imaging in the diagnosis of prostate cancer in patients with prior negative biopsies Eur Urol 2019 75 582 90 10.1016/j.eururo.2018.11.040 Open DOISearch in Google Scholar

22. Simmons LAM, Kanthabalan A, Arya M, Briggs T, Barratt D, Charman SC, et al. Accuracy of transperineal targeted prostate biopsies, visual estimation and image fusion in men needing repeat biopsy in the PICTURE Trial. J Urol 2018; 200: 1227–34. doi: 10.1016/j.juro.2018.07.001 SimmonsLAM KanthabalanA AryaM BriggsT BarrattD CharmanSC Accuracy of transperineal targeted prostate biopsies, visual estimation and image fusion in men needing repeat biopsy in the PICTURE Trial J Urol 2018 200 1227 34 10.1016/j.juro.2018.07.001 Open DOISearch in Google Scholar

23. Wegelin O, van Melick HHE, Hooft L, Bosch J, Reitsma HB, Barentsz JO, et al. Comparing three different techniques for magnetic resonance imaging-targeted prostate biopsies: a systematic review of in-bore versus magnetic resonance imaging-transrectal ultrasound fusion versus cognitive registration. Is there a preferred technique? Eur Urol 2017; 71: 517–31. doi: 10.1016/j.eururo.2016.07.041 WegelinO van MelickHHE HooftL BoschJ ReitsmaHB BarentszJO Comparing three different techniques for magnetic resonance imaging-targeted prostate biopsies: a systematic review of in-bore versus magnetic resonance imaging-transrectal ultrasound fusion versus cognitive registration. Is there a preferred technique? Eur Urol 2017 71 517 31 10.1016/j.eururo.2016.07.041 Open DOISearch in Google Scholar

24. Watts KL, Frechette L, Muller B, Ilinksy D, Kovac E, Sankin A, et al. Systematic review and meta-analysis comparing cognitive vs. image-guided fusion prostate biopsy for the detection of prostate cancer. Urol Oncol 2020; 38: 734 e19–e25. doi: 10.1016/j.urolonc.2020.03.020 WattsKL FrechetteL MullerB IlinksyD KovacE SankinA Systematic review and meta-analysis comparing cognitive vs. image-guided fusion prostate biopsy for the detection of prostate cancer Urol Oncol 2020 38 734 e19 e25 10.1016/j.urolonc.2020.03.020 Open DOISearch in Google Scholar

25. Smrkolj T. [Transrectal ultrasound and needle biopsy of the prostate]. [Slovenian]. Zdrav Vestn 2015; 84: 834–42. doi: 10.6016/ZdravVestn.1299 SmrkoljT [Transrectal ultrasound and needle biopsy of the prostate]. [Slovenian] Zdrav Vestn 2015 84 834 42 10.6016/ZdravVestn.1299 Open DOISearch in Google Scholar

26. Ortner G, Mavridis C, Fritz V, Schachtner J, Mamoulakis C, Nagele U, et al. The added value of MRI-based targeted biopsy in biopsy-naive patients: a propensity-score matched comparison. J Clin Med 2024; 13: 1. doi: 10.3390/jcm13051355 OrtnerG MavridisC FritzV SchachtnerJ MamoulakisC NageleU The added value of MRI-based targeted biopsy in biopsy-naive patients: a propensity-score matched comparison J Clin Med 2024 13 1 10.3390/jcm13051355 Open DOISearch in Google Scholar

27. Connor MJ, Miah S, Jayadevan R, Khoo CC, Eldred-Evans D, Shah T, et al. Value of systematic sampling in an mpMRI targeted prostate biopsy strategy. Transl Androl Urol 2020; 9: 1501–9. doi: 10.21037/tau.2019.07.16 ConnorMJ MiahS JayadevanR KhooCC Eldred-EvansD ShahT Value of systematic sampling in an mpMRI targeted prostate biopsy strategy Transl Androl Urol 2020 9 1501 9 10.21037/tau.2019.07.16 Open DOISearch in Google Scholar

28. Malewski W, Milecki T, Szemplinski S, Tayara O, Kuncman L, Kryst P, et al. Prostate biopsy in the case of PIRADS 5 - is systematic biopsy mandatory? J Clin Med 2023; 12: 5612. doi: 10.3390/jcm12175612 MalewskiW MileckiT SzemplinskiS TayaraO KuncmanL KrystP Prostate biopsy in the case of PIRADS 5 - is systematic biopsy mandatory? J Clin Med 2023 12 5612 10.3390/jcm12175612 Open DOISearch in Google Scholar

29. Kasabwala K, Patel N, Cricco-Lizza E, Shimpi AA, Weng S, Buchmann RM, et al. The learning curve for magnetic resonance imaging/ultrasound fusion-guided prostate biopsy. Eur Urol Oncol 2019; 2: 135–40. doi: 10.1016/j.euo.2018.07.005 KasabwalaK PatelN Cricco-LizzaE ShimpiAA WengS BuchmannRM The learning curve for magnetic resonance imaging/ultrasound fusion-guided prostate biopsy Eur Urol Oncol 2019 2 135 40 10.1016/j.euo.2018.07.005 Open DOISearch in Google Scholar

30. Xu L, Ye NY, Lee A, Chopra J, Naslund M, Wong-You-Cheong J, et al. Learning curve for magnetic resonance imaging/ultrasound fusion prostate biopsy in detecting prostate cancer using cumulative sum analysis. Curr Urol 2023; 17: 159–64. doi: 10.1097/CU9.0000000000000116 XuL YeNY LeeA ChopraJ NaslundM Wong-You-CheongJ Learning curve for magnetic resonance imaging/ultrasound fusion prostate biopsy in detecting prostate cancer using cumulative sum analysis Curr Urol 2023 17 159 64 10.1097/CU9.0000000000000116 Open DOISearch in Google Scholar

31. Mager R, Brandt MP, Borgmann H, Gust KM, Haferkamp A and Kurosch M. From novice to expert: analyzing the learning curve for MRI-transrectal ultrasonography fusion-guided transrectal prostate biopsy. Int Urol Nephrol 2017; 49: 1537–44. doi: 10.1007/s11255-017-1642-7 MagerR BrandtMP BorgmannH GustKM HaferkampA KuroschM From novice to expert: analyzing the learning curve for MRI-transrectal ultrasonography fusion-guided transrectal prostate biopsy Int Urol Nephrol 2017 49 1537 44 10.1007/s11255-017-1642-7 Open DOISearch in Google Scholar

32. Turchi B, Lombardo R, Franco A, Tema G, Nacchia A, Cicione A, et al. Residents and consultants have equal outcomes when performing transrectal fusion biopsies: a randomized clinical trial. Curr Oncol 2024; 31: 747–58. doi: 10.3390/curroncol31020055 TurchiB LombardoR FrancoA TemaG NacchiaA CicioneA Residents and consultants have equal outcomes when performing transrectal fusion biopsies: a randomized clinical trial Curr Oncol 2024 31 747 58 10.3390/curroncol31020055 Open DOISearch in Google Scholar

33. Rodriguez-Cabello MA, Mendez-Rubio S, Sanz-Miguelanez JL, Moraga-Sanz A, Aullo-Gonzalez C and Platas-Sancho A. Prevalence and grade of malignancy differences with respect to the area of involvement in multiparametric resonance imaging of the prostate in the diagnosis of prostate cancer using the PI-RADS version 2 classification. World J Urol 2023; 41: 2155–63. doi: 10.1007/s00345-023-04466-0 Rodriguez-CabelloMA Mendez-RubioS Sanz-MiguelanezJL Moraga-SanzA Aullo-GonzalezC Platas-SanchoA Prevalence and grade of malignancy differences with respect to the area of involvement in multiparametric resonance imaging of the prostate in the diagnosis of prostate cancer using the PI-RADS version 2 classification World J Urol 2023 41 2155 63 10.1007/s00345-023-04466-0 Open DOISearch in Google Scholar

34. Schlenker B, Apfelbeck M, Armbruster M, Chaloupka M, Stief CG and Clevert DA. Comparison of PIRADS 3 lesions with histopathological findings after MRI-fusion targeted biopsy of the prostate in a real world-setting. Clin Hemorheol Microcirc 2019; 71: 165–70. doi: 10.3233/CH-189407 SchlenkerB ApfelbeckM ArmbrusterM ChaloupkaM StiefCG ClevertDA Comparison of PIRADS 3 lesions with histopathological findings after MRI-fusion targeted biopsy of the prostate in a real world-setting Clin Hemorheol Microcirc 2019 71 165 70 10.3233/CH-189407 Open DOISearch in Google Scholar

35. Nicola R and Bittencourt LK. PIRADS 3 lesions: a critical review and discussion of how to improve management. Abdom Radiol (NY) 2023; 48: 2401–5. doi: 10.1007/s00261-023-03929-7 NicolaR BittencourtLK PIRADS 3 lesions: a critical review and discussion of how to improve management Abdom Radiol (NY) 2023 48 2401 5 10.1007/s00261-023-03929-7 Open DOISearch in Google Scholar

36. Patel HD, Halgrimson WR, Sweigert SE, Shea SM, Turk TMT, Quek ML, et al. Variability in prostate cancer detection among radiologists and urologists using MRI fusion biopsy. BJUI Compass 2024; 5: 304–12. doi: 10.1002/bco2.294 PatelHD HalgrimsonWR SweigertSE SheaSM TurkTMT QuekML Variability in prostate cancer detection among radiologists and urologists using MRI fusion biopsy BJUI Compass 2024 5 304 12 10.1002/bco2.294 Open DOISearch in Google Scholar

37. Berry B, Parry MG, Sujenthiran A, Nossiter J, Cowling TE, Aggarwal A, et al. Comparison of complications after transrectal and transperineal prostate biopsy: a national population-based study. BJU Int 2020; 126: 97–103. doi: 10.1111/bju.15039 BerryB ParryMG SujenthiranA NossiterJ CowlingTE AggarwalA Comparison of complications after transrectal and transperineal prostate biopsy: a national population-based study BJU Int 2020 126 97 103 10.1111/bju.15039 Open DOISearch in Google Scholar

38. Mian BM, Feustel PJ, Aziz A, Kaufman RP, Jr., Bernstein A, Avulova S, et al. Complications following transrectal and transperineal prostate biopsy: results of the ProBE-PC Randomized Clinical Trial. J Urol 2024; 211: 205–13. doi: 10.1097/JU.0000000000003788 MianBM FeustelPJ AzizA KaufmanRPJr. BernsteinA AvulovaS Complications following transrectal and transperineal prostate biopsy: results of the ProBE-PC Randomized Clinical Trial J Urol 2024 211 205 13 10.1097/JU.0000000000003788 Open DOISearch in Google Scholar